User profiles for F. Barkhof

Frederik Barkhof

VU University Medical Center
Verified email at vumc.nl
Cited by 168633

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

AJ Thompson, BL Banwell, F Barkhof… - The Lancet …, 2018 - thelancet.com
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research
and clinical practice. Scientific advances in the past 7 years suggest that they might no …

Defining the clinical course of multiple sclerosis: the 2013 revisions

…, JS Wolinsky, LJ Balcer, B Banwell, F Barkhof… - Neurology, 2014 - AAN Enterprises
F. Barkhof serves as a consultant for Bayer-Schering Pharma, Sanofi-Aventis, Biogen Idec,
Teva, Merck Serono, Novartis, Roche, Synthon, and Jansen Research. B. Bebo reports no …

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.

F Barkhof, M Filippi, DH Miller… - Brain: a journal of …, 1997 - academic.oup.com
We compared MRI criteria used to predict conversion of suspected multiple sclerosis to
clinically definite multiple sclerosis. Seventy-four patients with clinically isolated neurological …

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration

…, R Frayne, RI Lindley, JT O'Brien, F Barkhof… - The Lancet …, 2013 - thelancet.com
Cerebral small vessel disease (SVD) is a common accompaniment of ageing. Features
seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter …

Consistent resting-state networks across healthy subjects

…, SARB Rombouts, F Barkhof… - Proceedings of the …, 2006 - National Acad Sciences
Functional MRI (fMRI) can be applied to study the functional connectivity of the human brain.
It has been suggested that fluctuations in the blood oxygenation level-dependent (BOLD) …

Atrophy of medial temporal lobes on MRI in" probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

P Scheltens, D Leys, F Barkhof, D Huglo… - Journal of Neurology …, 1992 - jnnp.bmj.com
Magnetic resonance imaging (MRI) has shown a great reduction in medial temporal lobe
and hippocampal volume of patients with Alzheimer's disease as compared to controls. …

A new rating scale for age-related white matter changes applicable to MRI and CT

LO Wahlund, F Barkhof, F Fazekas, L Bronge… - Stroke, 2001 - Am Heart Assoc
Background and Purpose—MRI is more sensitive than CT for detection of age-related white
matter changes (ARWMC). Most rating scales estimate the degree and distribution of …

Reduced resting-state brain activity in the “default network” in normal aging

…, CF Beckmann, EJS Arigita, F Barkhof… - Cerebral …, 2008 - academic.oup.com
Normal aging is associated with cognitive decline. Functions such as attention, information
processing, and working memory are compromised. It has been hypothesized that not only …

[HTML][HTML] Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

JA Cohen, F Barkhof, G Comi… - … England Journal of …, 2010 - Mass Medical Soc
Background Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that
prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on …

[HTML][HTML] Two randomized phase 3 studies of aducanumab in early Alzheimer's disease

S Budd Haeberlein, PS Aisen, F Barkhof… - The journal of …, 2022 - Springer
Background Alzheimer’s disease is a progressive, irreversible, and fatal disease for which
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a …